Regeneron Pharmaceuticals, Inc.

Sanofi Biotechnology

Jennifer D Hamilton

Allen Radin

Neil John Graham

Namita A Gandhi

Marius Ardeleanu

Leda Mannent

Robert B Evans

Gianluca Pirozzi

Steven P Weinstein

Ariel Teper

Meagan P O'Brien

Brian Swanson

Sudeep Kundu

Ross E Rocklin

Jeffrey Ming

Sumathi Sivapalasingam

Gary Herman

Eduardo Forleo Neto

Brian N Swanson

Kenneth Turner

Flonza Isa

Andrea Hooper

Samit Ganguly

Stephane C Kirkesseli

Heribert Staudinger

Marcella Ruddy

Stephanie C Kirkesseli

Neil Graham

The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.

Methods for treating or preventing asthma by administering an IL-4R antagonist

The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

Methods for preventing or treating allergy by administering an IL-4R antagonist

The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

Methods for treating skin infection by administering an IL-4R antagonist

Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

The present invention provides methods for treating, preventing or reducing the severity of active eosinophilic esophagitis. In certain embodiments, the present invention provides methods of increasing esophageal distensibility. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4/interleukin-13 (IL-4/IL-13) pathway inhibitor such as an anti-IL-4R antibody.

Methods for treating active eosinophilic esophagitis

Growing community of inventors

Ridgefield, CT, United States of America

Jennifer D Hamilton